Our Services
Medical Information
Helpful Resources
Published on: 9/23/2026
Non-HDL cholesterol is your total cholesterol minus your HDL ("good") cholesterol, capturing every artery-clogging particle in your blood, including LDL, VLDL, and remnant lipoproteins, which makes it a stronger predictor of heart attack and stroke risk than LDL alone. For most adults, under 130 mg/dL is considered optimal, 130 to 159 mg/dL is near optimal, 160 to 189 mg/dL is borderline high, and 190 mg/dL or above is high, though people with diabetes or existing heart disease are often advised to stay under 100 mg/dL or even lower. Your personal target depends on several factors, including age, blood pressure, family history, and whether you smoke, so see below to understand more before drawing conclusions from a single number.
Because high non-HDL cholesterol causes no symptoms on its own, the warning signs people do notice, such as chest discomfort, shortness of breath, fatigue, or leg pain when walking, are worth taking seriously rather than waiting for the next routine blood panel. If anything feels off, a free, instant, online symptom check can help you organize what you are experiencing, see which conditions may explain it, and understand whether your next step should be a lipid panel, a primary care visit, or urgent attention.
Last reviewed for medical accuracy: 09/23/2026
What Is Non-HDL Cholesterol?
Non-HDL cholesterol is a measure of all the “bad” cholesterol in your blood. It includes low-density lipoprotein (LDL) plus very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and other atherogenic particles. Unlike total cholesterol, non-HDL gives a fuller picture of the cholesterol that can build up in your arteries and increase heart disease risk.
How Is Non-HDL Cholesterol Calculated?
You calculate non-HDL cholesterol by subtracting your HDL (“good” cholesterol) from your total cholesterol:
non-HDL = total cholesterol – HDL cholesterol
Because this uses values from a standard lipid panel (fasting not always required), it’s easy to get and track.
Why Non-HDL Matters
• More Accurate Risk Assessment
Studies show non-HDL is at least as good as LDL in predicting heart attack and stroke risk—and often better when triglycerides are high.
• Targets All Atherogenic Lipoproteins
By including VLDL and IDL, non-HDL accounts for remnants that can worsen artery plaque.
• Convenient and Cost-Effective
No extra tests are needed beyond your routine lipid panel.
What Counts as High Non-HDL Cholesterol?
Guidelines from leading organizations (American Heart Association, National Lipid Association) set non-HDL cholesterol targets based on overall heart risk.
General non-HDL Cholesterol Categories
• Optimal: less than 130 mg/dL
• Near or above optimal: 130–159 mg/dL
• Borderline high: 160–189 mg/dL
• High: 190–219 mg/dL
• Very high: 220 mg/dL and above
Patients at higher cardiovascular risk (existing heart disease, diabetes, chronic kidney disease) often have a lower non-HDL goal:
• Very high-risk target: non-HDL less than 100 mg/dL
If you have high non hdl cholesterol, your doctor may use these thresholds plus factors like age, blood pressure, smoking status and family history to decide if you need lifestyle changes, medication, or both.
Common Causes of High Non-HDL Cholesterol
• Poor Diet
– High in saturated fats (butter, fatty meats)
– Trans fats (commercial baked goods, fried foods)
– Excess refined carbohydrates and sugars
• Sedentary Lifestyle
– Low physical activity raises triglycerides and lowers HDL
• Obesity
– Excess weight, especially around the waist, worsens cholesterol profile
• Genetics
– Familial combined hyperlipidemia and other inherited disorders can elevate non-HDL
• Medical Conditions
– Diabetes, hypothyroidism, kidney disease and certain liver conditions
• Medications
– Some diuretics, steroids and antipsychotics can raise cholesterol levels
Symptoms and Why You Should Check—Even If You Feel Fine
High non-HDL cholesterol usually has no symptoms until plaque buildup narrows arteries enough to cause chest pain or a heart attack. That’s why routine blood tests are key. If you’re unsure about your symptoms or risk factors, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
How to Lower High Non-HDL Cholesterol
Monitoring and Follow-Up
• Frequency of Lipid Panels
– Every 4–12 weeks when starting or changing therapy
– Every 6–12 months once stable
• Track Other Markers
– LDL, HDL, triglycerides, blood pressure and blood sugar all contribute to your cardiovascular risk
• Share Results with Your Doctor
– Discuss any significant changes or if targets aren’t met
Balancing Realism and Reassurance
Having high non-HDL cholesterol doesn’t mean an immediate heart attack—many people manage it successfully with diet, exercise and medications. Stay proactive: know your numbers, follow your treatment plan and ask questions whenever you’re unsure.
When to Get Medical Help
Non-HDL cholesterol itself doesn’t cause pain, but complications might. Seek urgent care if you experience:
• Chest discomfort, pressure or tightness
• Shortness of breath not explained by exertion
• Sudden weakness or numbness, especially on one side of the body
• Sudden severe headache, vision changes or difficulty speaking
Always speak to a healthcare professional about anything that could be life threatening or serious.
Key Takeaways
• Non-HDL cholesterol measures all atherogenic particles—LDL, VLDL, IDL and more.
• Optimal non-HDL is <130 mg/dL; high non-HDL cholesterol starts at 190 mg/dL.
• Lifestyle changes are the first line: heart-healthy diet, exercise, weight management and quitting smoking.
• Medication may be necessary if your non-HDL remains high or if you have other risk factors.
• Regular lipid panels and open communication with your doctor help keep your heart healthy.
• If you’re unsure about symptoms or risks, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Nothing replaces personalized advice—always discuss your lipid results and health concerns with your doctor or a qualified healthcare provider.
(References)
* Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018 Oct;277:195-203. doi: 10.1016/j.atherosclerosis.2018.06.002. Epub 2018 Jun 12. PMID: 29910030.
* Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, Li D, Sievenpiper J, Duvnjak L, Vuksan V. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr. 2018 Nov 1;108(5):922-932. doi: 10.1093/ajcn/nqy115. PMID: 30239559.
* Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM, ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. PMID: 30403574.
* Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, Kelly S, Stroes ESG. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance. J Am Heart Assoc. 2019 Apr 2;8(7):e011662. doi: 10.1161/JAHA.118.011662. PMID: 30922146; PMCID: PMC6509724.
* Cicero AFG, Fogacci F, Banach M. Red Yeast Rice for Hypercholesterolemia. Methodist Debakey Cardiovasc J. 2019 Jul-Sep;15(3):192-199. doi: 10.14797/mdcj-15-3-192. PMID: 31687098; PMCID: PMC6822657.
* Cicero AFG, Fogacci F, Zambon A. Red Yeast Rice for Hypercholesterolemia: JACC Focus Seminar. J Am Coll Cardiol. 2021 Feb 9;77(5):620-628. doi: 10.1016/j.jacc.2020.11.056. PMID: 33538260.
* Liu C, Schönke M, Zhou E, Li Z, Kooijman S, Boon MR, Larsson M, Wallenius K, Dekker N, Barlind L, Peng XR, Wang Y, Rensen PCN. Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis. Cardiovasc Res. 2022 Jan 29;118(2):489-502. doi: 10.1093/cvr/cvab076. PMID: 33693480; PMCID: PMC8803070.
* Johannesen CDL, Mortensen MB, Langsted A, Nordestgaard BG. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021 Mar 23;77(11):1439-1450. doi: 10.1016/j.jacc.2021.01.027. PMID: 33736827.
* Yamashita S, Kiyosue A, Fujita H, Yokota D, Nakamura Y, Yasuda S. Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial). Circ J. 2025 Jul 25;89(8):1256-1265. doi: 10.1253/circj.CJ-25-0089. Epub 2025 Apr 28. PMID: 40159243.
* Navar AM, Mikhailova E, Catapano AL, Banka P, Blom DJ, Cadena A, Kourpanidis S, Lepor NE, Tsukamoto K, Mendizabal G, Nunez J, Zhang W, Zhu P, Zhuo M, Ballantyne CM, CORALreef Lipids Investigators. A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide. N Engl J Med. 2026 Feb 5;394(6):529-539. doi: 10.1056/NEJMoa2511002. PMID: 41879224.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.